Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms
There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 1998, Vol.18 (2), p.59-62 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 62 |
|---|---|
| container_issue | 2 |
| container_start_page | 59 |
| container_title | Rheumatology international |
| container_volume | 18 |
| creator | BOEHM, I. B BOEHM, G. A BAUER, R |
| description | There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10-25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5-24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens. |
| doi_str_mv | 10.1007/s002960050058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69995670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2428288501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-dd34b2db29350e7f2a7499530bfcaf9847eb9c903360fae3f9cd4a9d889d33873</originalsourceid><addsrcrecordid>eNpdkctrFTEUxoMo9bZ26VIIIt2Nnplk8nBXii9o6UahuyGThzdlklyTDPUu_N9NuZeCQjjh4_zOxzl8CL3u4X0PwD8UgEEygLE98Qxtekp41zO4e4420POhE628RKel3EPTjMEJOpFcDCOhG_TnRkX10wYbK04O67WqaNNa8LLuWrV5X7c2qJpKUw--bvGSHjqTisXB1m2q2f5W1eKP2Efjtao-RexSxiGZdTnI5uujW1R49Mn7Nqi3KvoSyiv0wqml2PPjf4Z-fP70_eprd3375dvV5XWnCaW1M4bQeTDzIMkIlrtBcSrlSGB2WjkpKLez1BIIYeCUJU5qQ5U0QkhDiODkDF0cfHc5_VptqVPwRdtlORw7MdnsGIcGvv0PvE9rjm23SQjaE0FgbFB3gHROpWTrpl32QeX91MP0mMn0TyaNf3M0XedgzRN9DKH13x37qmi1uKyi9uUJGwjrGSPkLwHBlis</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>884138305</pqid></control><display><type>article</type><title>Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>BOEHM, I. B ; BOEHM, G. A ; BAUER, R</creator><creatorcontrib>BOEHM, I. B ; BOEHM, G. A ; BAUER, R</creatorcontrib><description>There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10-25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5-24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens.</description><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s002960050058</identifier><identifier>PMID: 9782534</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antirheumatic Agents - therapeutic use ; Autoantibodies - blood ; Biological and medical sciences ; Dose-Response Relationship, Drug ; Drug therapy ; Female ; Humans ; Lupus Erythematosus, Cutaneous - drug therapy ; Lupus Erythematosus, Cutaneous - immunology ; Male ; Medical sciences ; Methotrexate - therapeutic use ; Middle Aged ; Retrospective Studies ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Treatment Outcome</subject><ispartof>Rheumatology international, 1998, Vol.18 (2), p.59-62</ispartof><rights>1998 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-dd34b2db29350e7f2a7499530bfcaf9847eb9c903360fae3f9cd4a9d889d33873</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2361663$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9782534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BOEHM, I. B</creatorcontrib><creatorcontrib>BOEHM, G. A</creatorcontrib><creatorcontrib>BAUER, R</creatorcontrib><title>Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><description>There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10-25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5-24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Autoantibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lupus Erythematosus, Cutaneous - drug therapy</subject><subject>Lupus Erythematosus, Cutaneous - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Treatment Outcome</subject><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkctrFTEUxoMo9bZ26VIIIt2Nnplk8nBXii9o6UahuyGThzdlklyTDPUu_N9NuZeCQjjh4_zOxzl8CL3u4X0PwD8UgEEygLE98Qxtekp41zO4e4420POhE628RKel3EPTjMEJOpFcDCOhG_TnRkX10wYbK04O67WqaNNa8LLuWrV5X7c2qJpKUw--bvGSHjqTisXB1m2q2f5W1eKP2Efjtao-RexSxiGZdTnI5uujW1R49Mn7Nqi3KvoSyiv0wqml2PPjf4Z-fP70_eprd3375dvV5XWnCaW1M4bQeTDzIMkIlrtBcSrlSGB2WjkpKLez1BIIYeCUJU5qQ5U0QkhDiODkDF0cfHc5_VptqVPwRdtlORw7MdnsGIcGvv0PvE9rjm23SQjaE0FgbFB3gHROpWTrpl32QeX91MP0mMn0TyaNf3M0XedgzRN9DKH13x37qmi1uKyi9uUJGwjrGSPkLwHBlis</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>BOEHM, I. B</creator><creator>BOEHM, G. A</creator><creator>BAUER, R</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms</title><author>BOEHM, I. B ; BOEHM, G. A ; BAUER, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-dd34b2db29350e7f2a7499530bfcaf9847eb9c903360fae3f9cd4a9d889d33873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Autoantibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lupus Erythematosus, Cutaneous - drug therapy</topic><topic>Lupus Erythematosus, Cutaneous - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOEHM, I. B</creatorcontrib><creatorcontrib>BOEHM, G. A</creatorcontrib><creatorcontrib>BAUER, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOEHM, I. B</au><au>BOEHM, G. A</au><au>BAUER, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms</atitle><jtitle>Rheumatology international</jtitle><addtitle>Rheumatol Int</addtitle><date>1998</date><risdate>1998</risdate><volume>18</volume><issue>2</issue><spage>59</spage><epage>62</epage><pages>59-62</pages><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10-25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5-24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>9782534</pmid><doi>10.1007/s002960050058</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0172-8172 |
| ispartof | Rheumatology international, 1998, Vol.18 (2), p.59-62 |
| issn | 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69995670 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Adult Aged Aged, 80 and over Antirheumatic Agents - therapeutic use Autoantibodies - blood Biological and medical sciences Dose-Response Relationship, Drug Drug therapy Female Humans Lupus Erythematosus, Cutaneous - drug therapy Lupus Erythematosus, Cutaneous - immunology Male Medical sciences Methotrexate - therapeutic use Middle Aged Retrospective Studies Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Treatment Outcome |
| title | Management of cutaneous lupus erythematosus with low-dose methotrexate : indication for modulation of inflammatory mechanisms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A53%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20cutaneous%20lupus%20erythematosus%20with%20low-dose%20methotrexate%20:%20indication%20for%20modulation%20of%20inflammatory%20mechanisms&rft.jtitle=Rheumatology%20international&rft.au=BOEHM,%20I.%20B&rft.date=1998&rft.volume=18&rft.issue=2&rft.spage=59&rft.epage=62&rft.pages=59-62&rft.issn=0172-8172&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s002960050058&rft_dat=%3Cproquest_cross%3E2428288501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=884138305&rft_id=info:pmid/9782534&rfr_iscdi=true |